Cryptotanshinone Suppressed Postmenopausal Osteoporosis by Preventing RANKL-Mediated Osteoclastogenesis Against Kidney Injury

    January 2022 in “ Evidence-based Complementary and Alternative Medicine ”
    Wenjiu Yang, Jing Han, Shuo Gong, Jun Zhao, Tengbo Yu, Jinfeng Ma
    Studysummary This study found that cryptotanshinone improved bone mass, inhibited osteoclast differentiation, and protected against kidney damage in ovariectomized rats, suggesting potential benefits for clinical use. Our plain-language summary of this paper — not a Tressless recommendation.
    The study investigated the effects of Cryptotanshinone (CPT) on postmenopausal osteoporosis using a rat model of OVX-induced osteoporosis. It found that CPT significantly improved bone mineral density and content, reduced bone loss, and enhanced collagen formation, indicating its potential to ameliorate osteoporosis. Additionally, CPT protected against kidney damage by reducing glomerular atrophy and normalizing creatinine levels. In vitro studies showed that CPT decreased the expression of osteoclast-specific proteins, suggesting its efficacy in inhibiting osteoclastogenesis. CPT exhibited no toxicity at doses below 10 µM, highlighting its safety as a treatment option for osteoporosis.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results